Castleman disease (CD) describes a group of heterogeneous hematologic disorders with
characteristic histopathological features. CD can present with unicentric or multicentric …

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The
anti–interleukin 6 (IL-6) therapy siltuximab is not available everywhere, and is not effective …

Castleman disease (CD) includes a group of rare and heterogeneous disorders with
characteristic lymph node histopathological abnormalities. CD can occur in a single lymph …

Castleman disease (CD) describes a heterogeneous group of hematologic disorders that
share characteristic lymph node histopathology. Patients of all ages present with either a …

Background Siltuximab is recommended by international consensus as a first-line treatment
for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety …

Summary Background Multicentric Castleman's disease describes a group of poorly
understood lymphoproliferative disorders driven by proinflammatory hypercytokinaemia …

Castleman disease (CD) is a nonclonal lymphoproliferative disorder that can affect single
lymph node stations or, alternatively, can be generalized. Interleukin 6 (IL6) plays a pivotal …

Background Castleman disease is an uncommon lymphoproliferative disorder characterized
as either unicentric or multicentric. Unicentric Castleman disease (UCD) is localized and …

Castleman disease (CD), a heterogeneous group of disorders that share morphological
features, is divided into unicentric CD and multicentric CD (MCD) according to the clinical …

Castleman disease (CD) comprises 3 poorly understood lymphoproliferative variants
sharing several common histopathological features. Unicentric CD (UCD) is localized to a …